Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy

This study tests whether a treatment using donated stem cells (allogeneic mesenchymal stem cells, or MSCs) can help patients with non-ischemic dilated cardiomyopathy (NIDCM) — a type of heart failure where the heart muscle becomes weakened and enlarged, but not because of blocked arteries. The MSCs are injected directly into the heart via a catheter-based procedure. Researchers hope this therapy can help the heart heal and pump better. You may be eligible if: - You are between 18 and 80 years old - You have been diagnosed with NIDCM and your heart's pumping function (ejection fraction) is 45% or less - You have been on stable, guideline-recommended heart failure medications (including beta blockers and ACE inhibitors/ARBs or equivalent) for at least 30 days - You are a candidate for cardiac catheterization and willing to undergo a DNA test You may NOT be eligible if: - You have or need surgical or interventional treatment for the cardiomyopathy - You have known coronary artery disease or signs of it on MRI - You have significant valve disease or severe aortic stenosis - You have cardiomyopathy due to hypertrophic, non-compaction, or recent postpartum causes - You have a QTc interval over 550 ms, severe anemia, significant kidney disease, liver dysfunction, bleeding disorder, or active infection - You are HIV positive, or have active Hepatitis B or C - You have had a cancer diagnosis in the last 12 months - You are pregnant or breastfeeding - You have other significant MRI contraindications Talk to your cardiologist if you have heart failure not caused by blocked arteries and want to explore this experimental stem cell therapy.